Pharma Body IDMA Names Dr T S Parmar as Secretary General
In a key leadership development for India’s pharmaceutical industry, the Indian Drugs Manufacturers’ Association (IDMA) has appointed Dr. T. S. Parmar as its new Secretary General, marking a transition at a time when the sector is navigating regulatory evolution, global supply chain realignments and rising compliance expectations.
Dr. Parmar succeeds Daara Patel, who led the association for over two decades and played a significant role in shaping IDMA’s policy engagement and industry representation.
With more than 33 years of experience across the pharmaceutical value chain, Dr. Parmar brings a combination of operational depth and strategic leadership to the role. His career spans senior positions at leading organisations including Boots/Knoll India, Eli Lilly India, Jubilant Life Sciences, Zydus Biochem and Zydus Cadila. Most recently, he served as Managing Director and Chief Executive Officer of Albert David.
Over the course of his career, he has managed end-to-end business functions, including P&L responsibility, corporate strategy and business development, while also overseeing manufacturing and international operations. His leadership track record includes steering business turnarounds, setting up greenfield pharmaceutical facilities and scaling large sales and marketing organisations in competitive therapeutic segments.
Dr. Parmar has also been closely associated with specialty therapy areas such as cardiology, diabetology, oncology and gynaecology, providing him with a strong understanding of both domestic and global healthcare market dynamics.
Beyond his corporate roles, he has remained actively engaged in academia and industry development. He has contributed as a mentor, healthcare advisor and author and has been associated with academic institutions as a member of Boards of Studies and as a guest faculty, reflecting a continued focus on knowledge sharing and talent development.
His appointment comes at a time when the pharmaceutical sector is increasingly required to balance growth ambitions with regulatory compliance, quality standards and global competitiveness. Industry bodies such as IDMA are expected to play a more active role in policy advocacy, stakeholder coordination and supporting member organisations through evolving market conditions.
Dr. Parmar’s blend of industry experience, strategic perspective and institutional engagement is expected to strengthen IDMA’s positioning as a key interface between policymakers and pharmaceutical manufacturers, particularly as the sector adapts to new global and domestic realities.
